Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2988729rdf:typepubmed:Citationlld:pubmed
pubmed-article:2988729lifeskim:mentionsumls-concept:C0019683lld:lifeskim
pubmed-article:2988729lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:2988729pubmed:issue12lld:pubmed
pubmed-article:2988729pubmed:dateCreated1985-8-12lld:pubmed
pubmed-article:2988729pubmed:abstractTextTesting for antibody to human T-lymphotropic retrovirus (HTLV-III) was carried out in 448 participants in the Vancouver Lymphadenopathy-AIDS (acquired immune deficiency syndrome) Study. The overall prevalence rate of seropositivity was 34%. Of 130 seronegative subjects followed for an average of 8.5 months, 14 became seropositive; thus, the approximate annual seroconversion rate was 15%. More than 100 male sexual partners in one's lifetime, frequent receptive anal intercourse, fisting, a history of gonorrhea or hepatitis, and frequent sexual contact in clubs were found to be independent risk factors for HTLV-III seropositivity.lld:pubmed
pubmed-article:2988729pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2988729pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2988729pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2988729pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2988729pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2988729pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2988729pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2988729pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2988729pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2988729pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2988729pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2988729pubmed:languageenglld:pubmed
pubmed-article:2988729pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2988729pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2988729pubmed:statusMEDLINElld:pubmed
pubmed-article:2988729pubmed:monthJunlld:pubmed
pubmed-article:2988729pubmed:issn0008-4409lld:pubmed
pubmed-article:2988729pubmed:authorpubmed-author:FazRRlld:pubmed
pubmed-article:2988729pubmed:authorpubmed-author:BoykoW JWJlld:pubmed
pubmed-article:2988729pubmed:authorpubmed-author:O'Shaughnessy...lld:pubmed
pubmed-article:2988729pubmed:authorpubmed-author:SchechterM...lld:pubmed
pubmed-article:2988729pubmed:authorpubmed-author:WiggsBBlld:pubmed
pubmed-article:2988729pubmed:authorpubmed-author:WilloughbyBBlld:pubmed
pubmed-article:2988729pubmed:authorpubmed-author:JeffriesEElld:pubmed
pubmed-article:2988729pubmed:issnTypePrintlld:pubmed
pubmed-article:2988729pubmed:day15lld:pubmed
pubmed-article:2988729pubmed:volume132lld:pubmed
pubmed-article:2988729pubmed:ownerNLMlld:pubmed
pubmed-article:2988729pubmed:authorsCompleteYlld:pubmed
pubmed-article:2988729pubmed:pagination1373-7lld:pubmed
pubmed-article:2988729pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:2988729pubmed:meshHeadingpubmed-meshheading:2988729-...lld:pubmed
pubmed-article:2988729pubmed:meshHeadingpubmed-meshheading:2988729-...lld:pubmed
pubmed-article:2988729pubmed:meshHeadingpubmed-meshheading:2988729-...lld:pubmed
pubmed-article:2988729pubmed:meshHeadingpubmed-meshheading:2988729-...lld:pubmed
pubmed-article:2988729pubmed:meshHeadingpubmed-meshheading:2988729-...lld:pubmed
pubmed-article:2988729pubmed:meshHeadingpubmed-meshheading:2988729-...lld:pubmed
pubmed-article:2988729pubmed:meshHeadingpubmed-meshheading:2988729-...lld:pubmed
pubmed-article:2988729pubmed:meshHeadingpubmed-meshheading:2988729-...lld:pubmed
pubmed-article:2988729pubmed:meshHeadingpubmed-meshheading:2988729-...lld:pubmed
pubmed-article:2988729pubmed:meshHeadingpubmed-meshheading:2988729-...lld:pubmed
pubmed-article:2988729pubmed:year1985lld:pubmed
pubmed-article:2988729pubmed:articleTitleThe Vancouver Lymphadenopathy-AIDS Study: 2. Seroepidemiology of HTLV-III antibody.lld:pubmed
pubmed-article:2988729pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2988729pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2988729lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2988729lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2988729lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2988729lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2988729lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2988729lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2988729lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2988729lld:pubmed